Medicare launched a formal process that will determine whether the agency will cover Aduhelm, the newly approved Alzheimer's drug whose high price tag and unproven benefits have prompted widespread controversy.
from WebMD Health https://ift.tt/36xHGHf
0 comments:
Post a Comment